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Imiquimod (IMQ) is a compound of the class of heterocyclic imidazoquinolines. 
It exhibits significant immunomodulatory effects after topical dermal application, thus it is 
used advantageously in the treatment of various viral or neoplastic skin diseases. The traded 
preparation Aldara
®
 containing 5% of the active substance IMQ has, despite its undeniable 
benefits in treatment, also a number of negative features: the price, the need for single use 
packets, side effects... 
The aim of this work was to formulate a stable dosage form for dermal administration 
of lower IMQ content (1%) and to compare the penetration and permeation rate of IMQ to 
human skin in vitro. To improve those qualities, permeation accelerants were used. 
Experiments were carried out in Franz's diffusion cells on human skin, with the aim of 
creating conditions as close as possible to those physiological. Using adhesive tapes, 
individual layers of the uppermost skin section (stratum corneum) were stripped, epidermis 
was separated from dermis and the treated tissue from the untreated one. The amount of IMQ 
in separated skin layers was analysed by HPLC. 
The evaluation was carried out in two application schemes: eight and twenty-four 
hours after the sample was applied. Most samples showed at least the same or higher IMQ 
levels in the epidermis after eight hours, compared with the control (Aldara
®
), even at half the 
amount of IMQ loaded. Promising formulations were those with predominant aqueous 
component (water or acetate buffer) with 2-Pro as an accelerant of and sorbitan oleate 
as an emulsifier (increase over Aldara
®
 2.5 and 1.7x respectively). This was confirmed 
by skin analysis after 24 hours when the difference in control vs. the IMQ dispersion with 
sorbitan and 2-Pro increased 7.8x, compared to epidermis concentration of IMQ after eight 
hours.  
 
